Get research updatesSchizophrenia can affect how a person perceives reality, thinks and feels, sometimes involving hearing voices or holding unusual beliefs.
Researchers studied SEP-363856, tracking side effects to assess safety and tolerability in people with schizophrenia.
This study has finished and is no longer accepting participants.
Multiple locations, including AnaheimResearchers are studying SEP-363856, tracking side effects to assess safety and tolerability in people with schizophrenia.
This study ended early.
Multiple locations, including Little RockAn Open-Label Positron Emission Tomography Study to Investigate the Effect of Adjunctive Administration of SEP-363856 on Brain Dopamine Synthesis Capacity Using 18F-DOPA in Adult Subjects With Schizophrenia
This study has finished and is no longer accepting participants.
In LondonA Randomized, Single-dose, Crossover Study of the Effects of SEP-363856 on Electrocardiogram (ECG) Intervals in Subjects With Schizophrenia
This study has finished and is no longer accepting participants.
Multiple locations, including Little RockA Double-Blind, Placebo-Controlled, Randomized Withdrawal Study to Evaluate SEP-363856 Physical Dependence in Adult Subjects With Schizophrenia
This study has finished and is no longer accepting participants.
Multiple locations, including Little RockA Randomized, Single-blind, Two-period Crossover to Investigate the Effect of SEP-363856 on the Pharmacokinetics of Metformin in Subjects With Schizophrenia.
This study has finished and is no longer accepting participants.
Multiple locations, including Oakland ParkResearchers compared SEP-363856 75mg, SEP-363856 100mg and placebo to find out how the approaches affected psychotic symptoms in people with schizophrenia.
This study has finished and is no longer accepting participants.
Multiple locations, including RogersThis study evaluated the safety of JX11502MA for people with schizophrenia.
This study has finished and is no longer accepting participants.
In ShanghaiResearchers are comparing SEP-363856 50 mg, SEP-363856 75 mg and placebo to find out how the approaches affect psychotic symptoms in people with schizophrenia.
This study ended early.
Multiple locations, including BeijingResearchers are studying SEP-363856, tracking side effects to assess long-term safety and tolerability in people with schizophrenia.
This study ended early.
Multiple locations, including Konan-shiResearchers compared SEP-363856 50mg, SEP-363856 75mg and placebo to find out how the approaches affected psychotic symptoms in people with schizophrenia.
This study has finished and is no longer accepting participants.
Multiple locations, including Little RockA Phase 3, Multicenter, Double-Blind Comparison of LY2140023 and Aripiprazole in Patients With DSM-IV-TR Schizophrenia Followed by Open-Label Treatment With LY2140023
This study ended early.
Multiple locations, including CerritosWe gather information about mental health clinical trials from the public registries we index. Coverage is still expanding, so some studies may not appear yet.